SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2019
SURFACE ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
50 Hampshire Street, 8th Floor
Cambridge, MA 02139
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|Item 8.01.|| |
On February 4, 2019, Surface Oncology, Inc. issued a press release announcing its retention of worldwide rights for its antibody, SRF388, targeting IL-27. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|Item 9.01.|| |
Financial Statements and Exhibits.
|99.1||Press release issued by Surface Oncology, Inc., dated February 4, 2019|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Surface Oncology, Inc.|
|Date: February 4, 2019||By:||/s/ J. Jeffrey Goater|
J. Jeffrey Goater
President and Chief Executive Officer
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
IL-27 is a key regulator of checkpoint protein expression
SRF388 believed to be the only anti-IL-27 targeted agent in late-preclinical development
Investigational New Drug (IND) submission for SRF388 expected in Q4 2019
CAMBRIDGE, Mass., Feb. 4, 2019 (GLOBE NEWSWIRE) Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting IL-27. This program was previously subject to Surfaces collaboration with Novartis. IL-27 is a novel target in immuno-oncology, believed to play a significant and broad role in tumor-related immunosuppression via the regulation of checkpoint protein expression.
SRF388 is an ideal program for Surface Oncology. We have conducted significant preclinical and translational work to understand IL-27s role in specific tumor types and have a focused translational strategy as we advance this program into clinical development, said Jeff Goater, chief executive officer of Surface Oncology. We are pursuing an aggressive development timeline for SRF388, with an IND filing planned for the fourth quarter of this year.
Based on the terms of the 2016 agreement with Novartis, IL-27 was one of a set of predefined targets for which Novartis had a right to purchase an option, subject to certain financial conditions. Novartis has elected to not purchase an option for SRF388 and as a result full rights remain with Surface Oncology.
Currently, Surface Oncology is conducting IND-enabling studies for both SRF388 and its wholly owned CD39 program, SRF617, and anticipates submission of both INDs in Q4 of 2019.
SRF388 is a fully human anti-IL-27 antibody. In preclinical studies, treatment with SRF388 was observed to block IL-27 signaling and its downstream immunosuppressive effects. Preclinical combination with a PD-1 inhibitor increased the production of key inflammatory cytokines. SRF388 also demonstrates preclinical anti-metastatic tumor activity.
Surface Oncology | 50 Hampshire Street, 8th Floor| Cambridge, MA 02139
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surfaces novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to two next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com
Ten Bridge Communications
Cautionary Note Regarding Forward-Looking Statements:
Certain statements set forth in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as believes, expects, plans, potential, would or similar expressions and the negative of those terms. These forward-looking statements are based on Surface Oncologys managements current beliefs and assumptions about future events and on information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Surface Oncologys actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. These risks include, but are not limited to, risks and uncertainties related to Surface Oncologys ability to successfully develop SRF388, SRF617 and its other product candidates through current and future milestones or regulatory filings on the anticipated timeline, if at all, the therapeutic potential of Surface Oncologys product candidates, the risk that results from preclinical studies or early clinical trials may not be representative of larger clinical trials, the risk that Surface Oncologys product candidates, including SRF388 and SRF617, will not be successfully developed or commercialized and the risks related to Surface Oncologys dependence on third parties in connection with its manufacturing, clinical trials and preclinical studies. Additional risks and uncertainties that could affect Surface Oncologys future results are included in the section titled Risk Factors in our Quarterly Report on Form 10-Q for the period ending September 30, 2018, which is available on the Security and Exchange Commissions website at www.sec.gov and Surface Oncologys website at www.surfaceoncology.com.
Additional information on potential risks will be made available in other filings that Surface Oncology makes from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date. Except as required by law, Surface Oncology assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.